Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey.

Autor: Wood MS; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America., Halmer N; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America., Bertolli J; Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America., Amsden LB; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America., Nugent JR; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America., Lin JS; Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America., Rothrock G; California Emerging Infections Program, Oakland, CA, United States of America., Nadle J; California Emerging Infections Program, Oakland, CA, United States of America., Chai SJ; Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.; California Emerging Infections Program, Oakland, CA, United States of America., Cope JR; Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America., Champsi JH; The Permanente Medical Group, Kaiser Permanente Northern California, Oakland, CA, United States of America.; Department of Infectious Diseases, South San Francisco Medical Center, Kaiser Permanente Northern California, South San Francisco, CA, United States of America., Yang J; The Permanente Medical Group, Kaiser Permanente Northern California, Oakland, CA, United States of America.; Department of Adult and Family Medicine, Roseville Riverside Medical Offices, Kaiser Permanente Northern California, Roseville, CA, United States of America., Unger ER; Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America., Skarbinski J; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America.; The Permanente Medical Group, Kaiser Permanente Northern California, Oakland, CA, United States of America.; Department of Infectious Diseases, Oakland Medical Center, Kaiser Permanente Northern California, Oakland, CA, United States of America.; Physician Researcher Program, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2024 Sep 18; Vol. 19 (9), pp. e0309810. Date of Electronic Publication: 2024 Sep 18 (Print Publication: 2024).
DOI: 10.1371/journal.pone.0309810
Abstrakt: Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can be triggered by infectious agents including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the impact of the coronavirus disease 2019 (COVID-19) pandemic on ME/CFS prevalence is not well characterized.
Methods: In this population-based cross-sectional study, we enrolled a stratified random sample of 9,825 adult participants in the Kaiser Permanente Northern California (KPNC) integrated health system from July to October 2022 to assess overall ME/CFS-like illness prevalence and the proportion that were identified following COVID-19 illness. We used medical record and survey data to estimate the prevalence of ME/CFS-like illness based on self-reported symptoms congruent with the 2015 Institute of Medicine ME/CFS criteria. History of COVID-19 was based on a positive SARS-CoV-2 nucleic acid amplification test or ICD-10 diagnosis code in the medical record, or self-report of prior COVID-19 on a survey.
Results: Of 2,745,374 adults in the eligible population, an estimated 45,892 (95% confidence interval [CI]: 32,869, 58,914) or 1.67% (CI 1.20%, 2.15%) had ME/CFS-like illness. Among those with ME/CFS-like illness, an estimated 14.12% (CI 3.64%, 24.6%) developed the illness after COVID-19. Among persons who had COVID-19, those with ME/CFS-like illness after COVID-19 were more likely to be unvaccinated and to have had COVID-19 before June 1, 2021. All persons with ME/CFS-like illness had significant impairment in physical, mental, emotional, social, and occupational functioning compared to persons without ME/CFS-like illness.
Conclusions: In a large, integrated health system, 1.67% of adults had ME/CFS-like illness and 14.12% of all persons with ME/CFS-like illness developed it after COVID-19. Though COVID-19 did not substantially increase ME/CFS-like illness in the KPNC population during the study time period, ME/CFS-like illness nevertheless affects a notable portion of this population and is consistent with estimates of ME/CFS prevalence in other populations. Additional attention is needed to improve awareness, diagnosis, and treatment of ME/CFS.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje